##ANALYSISTYPE=CFDNA
##PIPELINE=megSAP 2024_09-116-gd10ae941
##GENOME_BUILD=GRCh38
##CREATION_DATE=2024-12-22
##CALLING_DATE=22/1-2/-2024
##FILTER=Clustered_Variant=Clustered variants
##FILTER=Error=Alternative counts inside the expected error rate distribution
##FILTER=FDR=no description available
##FILTER=Fisher_Strand=Strand bias based on fisher test
##FILTER=LC_Downstream=Low complexity region (5bps) downstream. ≥ 80% of bases show the same nucleotide  or tandem of ≥ 3 equal nucleotides in a row
##FILTER=LC_Upstream=Low complexity region (5bps) upstream. ≥ 80% of bases show the same nucleotide or tandem of ≥ 3 equal nucleotides in a row
##FILTER=Low_AC=Less than defined minimum of alternative counts
##FILTER=low_conf_region=Variant marked as 'low_conf_region'.
##FILTER=Low_COV=Low coverage
##FILTER=Low_qual_pos=Position enriched with too many low quality bases
##FILTER=No_Coverage=No read coverage for this monitoring/ID variant in BAM file.
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=PASS=Passed filter
##FILTER=Strand_imbalanced=All alternative reads found in only one strand
##FILTER=Variant_contamination=Reads supporting other alleles outside of the error rate distribution
##SAMPLE=<ID=CFDNA_01,IsTumor=yes>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), quality divided by depth (QD), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous/hemizygous case count of gnomAD project (genome data).
##DESCRIPTION=gnomAD_het=Heterozygous allele count of the gnomAD project (genome data).
##DESCRIPTION=gnomAD_wt=Wildtype allele count of the gnomAD project (genome data).
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=AlphaMissense=AlphaMissense pathogenicity score. Deleterious threshold > 0.564.
##DESCRIPTION=MaxEntScan=MaxEntScan reference score and alternate score for (1) native splice site, (2) acceptor gain and (3) donor gain. Comma-separated list if there are different predictions for several transcripts.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=SpliceAI=SpliceAI prediction. These include delta scores (DS) and delta positions (DP) for acceptor gain (AG), acceptor loss (AL), donor gain (DG), and donor loss (DL). Format: GENE|DS_AG|DS_AL|DS_DG|DS_DL|DP_AG|DP_AL|DP_DG|DP_DL.
##DESCRIPTION=PubMed=PubMed ids to publications on the given variant.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_mosaic=Mosaic variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample CFDNA_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample CFDNA_01).
##DESCRIPTION=p-value=Uncorrected p-value
##DESCRIPTION=m_AF=Multi-UMI alternative allele fraction
##DESCRIPTION=m_REF=Multi-UMI reference-like read counts
##DESCRIPTION=m_ALT=Multi-UMI alternative read counts
##DESCRIPTION=Strand=Alleles in strands: Alternative forward, Alternative reverse, Reference forward, Reference reverse
##DESCRIPTION=Sequence context=Sequence +/- 5bp around the variant.
##DESCRIPTION=Homopolymer=Indicates if variant is in a homopolymer region.
##DESCRIPTION=somatic_classification_comment=Somatic classification comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
#chr	start	end	ref	obs	tumor_af	tumor_dp	p-value	Alt counts	m_AF	m_REF	m_ALT	Strand	Sequence context	Homopolymer	filter	quality	gene	variant_type	coding_and_splicing	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	gnomAD	gnomAD_sub	gnomAD_hom_hemi	gnomAD_het	gnomAD_wt	phyloP	CADD	REVEL	AlphaMissense	MaxEntScan	COSMIC	SpliceAI	PubMed	NGSD_som_c	NGSD_som_p	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_mosaic	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT	Tumor_Filter	Post_Filter
chr1	114713909	114713909	G	T	0.0107	3165	0.000157	34	0.00898	1876	17	25-9-2443-688	TTCTTGTCCAG	False		QUAL=0	NRAS	missense	NRAS:ENST00000369535.5:missense_variant:MODERATE:exon3/7:c.181C>A:p.Gln61Lys:PF00071 [Ras family]		164790_[GENE=NRAS_PHENOS=Noonan syndrome 6, 613224 (3), Autosomal dominant; ?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 (3); Melanocytic nevus syndrome, congenital, somatic, 137550 (3); Epidermal nevus, somatic, 162900 (3); Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3); Thyroid carcinoma, follicular, somatic, 188470 (3); Neurocutaneous melanosis, somatic, 249400 (3); Colorectal cancer, somatic, 114500 (3)]	73058 [likely pathogenic(replaced by megSAP based on classifications:1x3,2x5) DISEASE=Neoplasm of the large intestine,Neoplasm of brain,Multiple myeloma,Neuroblastoma,Malignant melanoma of skin,Ras Inhibitor response,Transitional cell carcinoma of the bladder,RASopathy,Vascular Tumors Including Pyogenic Granuloma,Melanoma,not provided,Gastric adenocarcinoma,Ovarian serous cystadenocarcinoma,Nasopharyngeal neoplasm,Malignant neoplasm of body of uterus,Adrenal cortex carcinoma,Acute myeloid leukemia,Hepatocellular carcinoma,Papillary renal cell carcinoma type 1,Non-small cell lung carcinoma,Glioblastoma,Lung adenocarcinoma,Large congenital melanocytic nevus,Neurocutaneous melanocytosis,B-cell chronic lymphocytic leukemia GENE=NRAS];			rs121913254						9.865	26.7	0.841	0.99	/0.0>0.0/0.0>0.0	COSV54736310,COSV54743343,COSV54752117	NRAS|0.00|0.00|0.00|0.00|12|41|5|-7	2674680,8120410,12460918,16273091,16291983,17699718,18390968,18633438,18948947,20130576,20179705,20619739,20736745,21107323,21305640,21729679,21829508,22761467,23392294,23414587,23515407,23538902,23569304,23614898,25157968,26619011,19657110,19966803,23076151,26821351,24148783,23400451,25695684,25348872,24671188,15899789,27050078,22718121,28780248,10821536,18668139,37384296	123	22075I_0981_mucosal-melanoma_efi,AxelMelanomaPhD,Novartis,Siena_1328_Mel_WES,SomaticAndTreatment,Test_Twist_Exome_Covaris,practical_training	ONCOGENIC	ClinVar Klasse 4 COSMIC Recurrence >1400 OncoKB & Cancer Hotspot	0	3	1	0 / 0		[import GPD] Christopher Schroeder 2013-09-09 11:18:14 -type: lit / general -link: http://jco.ascopubs.org/content/31/26/3173?cmpid=jco_etoc_10September2013 -doi: 10.1200/JCO.2013.50.3144 -drugs: imatinib Another Option in Our KIT of Effective Therapies for Advanced Melanoma => Of 24 evaluable patients, seven achieved a partial response (PR) to therapy, with five patients' responses confirmed on subsequent imaging studies, for an overall confirmed response rate (RR) of 21%. This clinical activity is similar to that observed in two other trials of imatinib in patients with melanoma molecularly selected for the presence of KIT alterations. Our group3 screened 295 patients for KIT mutations or amplification, identified 51 patients with such alterations, treated 25 evaluable patients, and observed a confirmed RR of 16%, with responses durable for longer than 1 year. Guo et al4 screened 501 patients for KIT mutations or amplification, treated 43 patients with imatinib, and observed an RR of 23.3%. The significance of the responses observed on these three trials is most evident when placed in the context of three prior negative phase II trials of imatinib in molecularly unselected melanoma patients initiated before the identification of KIT mutations in this disease, in which only one radiographic response was observed in 62 patients treated across the three trials.5â7  => Although approximately 70% of KIT mutations identified in melanoma affect the juxtamembrane domain (exon 11, most commonly L576P) and the proximal kinase domain (exon 13, most commonly K642E), others have been identified that likely represent passenger mutations of no biologic significance.  => NRAS Q61K mutation plus a previously detected W557G KIT mutation was also identified in a secondarily resistant tumor after a 7-month course of sunitinib, suggesting that NRAS mutations may also be a mechanism of secondary resistance to KIT inhibition.12,14 [3] ahwittd1 08.04.2020 [5] ahwittd1 08.04.2020 [n/a] ahwittd1 08.04.2020	activating	[activating] ahwittd1 08.04.2020  Hospotmutation.			NRAS (inh=AD oe_syn=1.00 oe_mis=0.53 oe_lof=0.19), CSDE1 (inh=n/a oe_syn=0.96 oe_mis=0.55 oe_lof=0.05)	NRAS	COSV54736310	NS/malignant_melanoma/NS=83/2213=3.75%;haematopoietic_and_lymphoid_tissue/haematopoietic_neoplasm/acute_myeloid_leukaemia=128/10064=1.27%;haematopoietic_and_lymphoid_tissue/haematopoietic_neoplasm/acute_myeloid_leukaemia_therapy_related=7/281=2.49%;haematopoietic_and_lymphoid_tissue/lymphoid_neoplasm/plasma_cell_myeloma=55/1340=4.1%;large_intestine/adenoma/NS=4/348=1.15%;lung/carcinoma/large_cell_carcinoma=4/255=1.57%;ovary/carcinoma/serous_carcinoma=6/468=1.28%;skin/benign_melanocytic_nevus/NS=11/334=3.29%;skin/benign_melanocytic_nevus/compound=7/117=5.98%;skin/benign_melanocytic_nevus/congenital=111/303=36.63%;skin/benign_melanocytic_nevus/intradermal=6/87=6.9%;skin/malignant_melanoma/NS=466/10424=4.47%;skin/malignant_melanoma/acral_lentiginous=16/707=2.26%;skin/malignant_melanoma/epithelioid=4/65=6.15%;skin/malignant_melanoma/nodular=54/639=8.45%;skin/malignant_melanoma/spitzoid=5/190=2.63%;skin/malignant_melanoma/superficial_spreading=61/752=8.11%;skin/malignant_melanoma/vertical_growth_phase=13/152=8.55%;soft_tissue/rhabdomyosarcoma/embryonal=27/315=8.57%;testis/germ_cell_tumour/seminoma=4/326=1.23%;thyroid/carcinoma/anaplastic_carcinoma=35/676=5.18%;thyroid/carcinoma/follicular_carcinoma=28/804=3.48%;thyroid/carcinoma/poorly_differentiated_carcinoma=12/400=3%;thyroid/other/neoplasm=11/132=8.33%	colon=2.8e-20;melanoma=3.09e-93;thyroid=2.47e-15	1	ENST00000369535:p.Gln61Lys	422	142		
chr1	114713915	114713915	C	T	0.0081	3342	0.00596	27	0.00923	1933	18	10-17-2613-700	TCCAGCTGTAT	False	FDR	QUAL=0	NRAS	missense	NRAS:ENST00000369535.5:missense_variant:MODERATE:exon3/7:c.175G>A:p.Ala59Thr:PF00071 [Ras family]		164790_[GENE=NRAS_PHENOS=Noonan syndrome 6, 613224 (3), Autosomal dominant; ?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 (3); Melanocytic nevus syndrome, congenital, somatic, 137550 (3); Epidermal nevus, somatic, 162900 (3); Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3); Thyroid carcinoma, follicular, somatic, 188470 (3); Neurocutaneous melanosis, somatic, 249400 (3); Colorectal cancer, somatic, 114500 (3)]	40473 [likely pathogenic(replaced by megSAP based on classifications:1x3,1x4,1x5) DISEASE=not provided,Noonan syndrome 6,Cardiovascular phenotype GENE=NRAS];			rs730880965						7.801	24.9	0.873	1	/0.0>0.0/0.0>0.0	COSV54743124,COSV54743482	NRAS|0.00|0.00|0.00|0.00|-13|-1|-13|-1	28594414	0				0	0	0	0 / 0							NRAS (inh=AD oe_syn=1.00 oe_mis=0.53 oe_lof=0.19), CSDE1 (inh=n/a oe_syn=0.96 oe_mis=0.55 oe_lof=0.05)	NRAS	COSV54743124			Other					
